ArticleClinical pharmacokinetics2016

Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.

Elodie Odore et al.PubMed ↗Publisher ↗

No numbers read from the abstract.